Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1717916

registered interest
date	14/05/2024
answering body	Department for Culture, Media and Sport
answering dept id	217
answering dept short name	Culture, Media and Sport
answering dept sort name	Culture, Media and Sport
hansard heading	Advertising: Internet
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Culture, Media and Sport, with reference to her Department’s publication entitled Government response to Online Advertising Programme consultation, updated on 25 July 2023, what assessment her Department has made of the adequacy of the evidence base for the (a) origin and (b) location of in-scope online advertising; and how that evidence will inform future policy decisions.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	26125
answer	answer is ministerial correction date of answer 22/05/2024 answer text <p>As set out in the Government’s response to the 2022 Online Advertising Programme consultation, the configuration of the market at present can mean that accessing comprehensive data on harms associated with online advertising can be challenging. We have already commissioned external research papers, conducted a call for evidence, and completed a public consultation, to seek to address this.</p><p>The Online Advertising Taskforce was established to encourage actors across the advertising industry to improve standards and build the evidence base on advertising harms and how they enter the supply chain, in advance of future legislation. As part of this work, DCMS is undertaking research on online users’ experiences of advertising harms. The Taskforce will publish a progress report on its work in the autumn.</p><p>The publication in due course of the second consultation on the Online Advertising Programme will also provide an opportunity for respondents to contribute additional evidence.</p> answering member constituency Hornchurch and Upminster answering member printed Julia Lopez question first answered 22/05/2024 10:47:50 answering member 4647 label Biography information for Julia Lopez
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699968

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of medication costs on community pharmacies.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20988
answer	answer is ministerial correction date of answer 19/04/2024 answer text <p>Through the medicine margin survey, the Department assesses whether the reimbursement arrangements pay pharmacy contractors as agreed as part of the community pharmacy contractual framework (CPCF). The medicine margin survey considers what pharmacies paid for medicines by looking at their invoices compared to the amount reimbursed by the National Health Service. Where the survey finds that they have been underpaid, we increase the pharmacy contractors’ payments, and where they have been overpaid, we decrease payments.</p><p>Furthermore, where pharmacies cannot purchase products at or below the Drug Tariff NHS reimbursement price, Community Pharmacy England can request that the Department reassesses the reimbursement price. If a new reimbursement price is issued, this is known as a concessionary price.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20979 question first answered 19/04/2024 09:54:36 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699969

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to increase core community pharmacy funding.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20989
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>As part of the Community Pharmacy Contractual Framework five-year deal, we committed £2.6 billion every year to community pharmacy, and agreed not to recover £212 million in over delivered fees and margin from community pharmacies in recent years. In addition, we are now investing up to £645 million across 2023/24 and 2024/25 in Pharmacy First, for more blood pressure checks and more contraception consultations in pharmacy. We have begun the consultation with Community Pharmacy England on the national funding and contractual framework arrangements for 2024/25.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 18/04/2024 16:00:23 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699970

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pharmacy: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to increase the scope of the Pharmacy First programme.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20990
answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Pharmacy First was launched on 31 January 2024, and as the service embeds, we will monitor and evaluate the service, and keep the conditions covered by Pharmacy First under review.</p> answering member constituency South Northamptonshire answering member printed Andrea Leadsom question first answered 18/04/2024 16:57:21 answering member 4117 label Biography information for Andrea Leadsom
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699971

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she plans to develop a Priority Review programme for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20991
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20992 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699972

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment: Reviews
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 23 June 2023 to Question 189729 on Medicines and Healthcare products Regulatory Agency, whether she plans to initiate a priority review for medical devices.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20992
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20993 question first answered 22/04/2024 11:22:39 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1699973

registered interest
date	12/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Equipment
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether (a) the Medicines and Healthcare products Regulatory Agency and (b) NICE will prioritise the regulatory timelines for medical devices that (i) respond to conditions outlined in the Major Conditions Strategy and (ii) where there is unmet need.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	20993
answer	answer is ministerial correction date of answer 22/04/2024 answer text <p>The Priority Review programme is not currently planned, but the Government is taking other significant steps for medical device regulatory reform, as part of a broader Medical Technology Strategy. Further information on the Medical Technology Strategy is available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy" target="_blank">https://www.gov.uk/government/publications/medical-technology-strategy/medical-technology-strategy</a></p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating medical devices, and designates United Kingdom Approved Bodies to conduct conformity assessments against the relevant regulatory requirements. The MHRA works closely with Approved Bodies to ensure their timely assessment.</p><p> </p><p>Following a consultation on the future regulation of medical devices in 2021, the MHRA is leading a programme of work to introduce updated regulations for medical devices that prioritise patient safety, improve patient access to innovative medical devices, and ensure the UK remains an attractive market for medical technology innovators. In January of this year, the MHRA published a MedTech Regulatory roadmap that sets out the main activities in implementing the future regulations throughout 2024 and 2025. An international recognition framework for medical devices will form part of the future regulatory framework, which will provide an alternative route to the UK’s market, by leveraging approvals from comparable international regulators. The MHRA aims to publish an outline of the International Recognition Framework for medical devices later this spring, aligned to the Life Sciences Council, subject to necessary approvals.</p><p>In addition, the MHRA is leading the reform of the medical devices regulatory landscape and includes a new pathway to accelerate access to safe, innovative medical devices to help meet the unmet needs of patients. The Innovative Devices Access Pathway aims to bring new medical technologies and solutions to the National Health Service, to support the medical needs that are not currently being met. There are eight innovative medical technologies included in the pilot phase.</p><p>We are working alongside others to further the Life Sciences Vision, particularly improving regulation and regulatory processes around medical devices, and supporting broader ambitions in the vision aligned to the conditions set out in the Major Conditions Strategy. As we work to update the medical devices regulatory landscape, the MHRA is taking the Major Conditions Strategy into consideration, including the six groups of major health conditions.</p><p>The National Institute for Health and Care Excellence (NICE) is not a regulator but makes recommendations for the NHS on whether selected medical devices should be routinely adopted by the NHS, based on an assessment of their costs and benefits. Medical devices are prioritised for the NICE’s evaluation, in line with NICE’s published topic selection manual.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20991 20992 question first answered 22/04/2024 11:22:40 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4008 label Biography information for Dame Caroline Dinenage

1698245

registered interest
date	19/03/2024
answering body	Ministry of Defence
answering dept id	11
answering dept short name	Defence
answering dept sort name	Defence
hansard heading	Military Bases: Gosport
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Defence, what progress his Department has made on the disposal of Fort Blockhouse in Gosport.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	902178
answer	answer is ministerial correction date of answer 25/03/2024 answer text <p>The MOD continues to work closely with Gosport Borough Council and wider stakeholders to realise the full opportunities and constraints for this site locally. This has included extensive surveys into influencing factors such as heritage, flood risk, and habitats. Our focus, however, at present remains the critical repair works following the damage inflicted on the historic sea walls by Storm Ciaran.</p> answering member constituency South Suffolk answering member printed James Cartlidge question first answered 25/03/2024 18:23:42 answering member 4519 label Biography information for James Cartlidge
tabling member	4008 label Biography information for Dame Caroline Dinenage

1684798

registered interest
date	24/01/2024
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Motorcycles: Carbon Emissions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, if he will make an assessment of the potential impact of (a) architectural and (b) safety requirements for L-Category vehicles on the transition of those vehicles to net zero emissions.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	11314
answer	answer is ministerial correction date of answer 30/01/2024 answer text <p>Zero emission L-category vehicles can currently be brought to market through the existing regulatory regime which includes electrical safety requirements. These type approval standards primarily flow from international regulations which are constantly monitored to ensure they remain fit for purpose with respect to evolving technology.</p><p>We expect to consult on introducing a new GB type approval scheme in the future which will provide an opportunity to reflect on the potential for new categories or technical requirements.</p> answering member constituency South Cambridgeshire answering member printed Anthony Browne question first answered 30/01/2024 16:02:31 answering member 4801 label Biography information for Anthony Browne
tabling member	4008 label Biography information for Dame Caroline Dinenage

1684799

registered interest
date	24/01/2024
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Motorcycles: Carbon Emissions
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Transport, pursuant to the Answer of 12 December 2023 to Question 5003 on Motor Vehicles: Exhaust Emissions, what assessment he has made of the potential impact on the UK L-Category sector of the creation of a new vehicle category as a result of regulatory misalignment with international markets.
tabling member constituency	Gosport
tabling member printed	Dame Caroline Dinenage
uin	11315
answer	answer is ministerial correction date of answer 30/01/2024 answer text <p>L-category vehicles must be type approved to technical standards that primarily flow from international regulations. These are constantly monitored to ensure they remain fit for purpose with respect to evolving technology.</p><p>We expect to consult on introducing a new GB type approval scheme in the future which will provide an opportunity to reflect on the potential for new categories and technical requirements.</p> answering member constituency South Cambridgeshire answering member printed Anthony Browne question first answered 30/01/2024 15:26:01 answering member 4801 label Biography information for Anthony Browne
tabling member	4008 label Biography information for Dame Caroline Dinenage